Our first product is a universal complement SARS coronavirus vaccine candidate. The antigen is designed to elicit a new class of antibodies neutralizing all new variants. The antigen is displayed on a self-assembling nanoparticle directly encoded by messenger RNAs. This nanoparticle enhances immune response, including long term adaptive cell-mediated immunity. The pursued advantages of our nanoparticle vaccine are longer protection, protection against viral dissemination and associated neuropathology, and reduction of the number of challenges necessary for immunization.